OrganiGram Holdings Inc. (TSE:OGI – Get Rating) – Analysts at Jefferies Financial Group lifted their Q3 2022 earnings estimates for shares of OrganiGram in a research report issued to clients and investors on Wednesday, April 13th. Jefferies Financial Group analyst O. Bennett now anticipates that the company will post earnings of ($0.02) per share for the quarter, up from their previous estimate of ($0.03). Jefferies Financial Group also issued estimates for OrganiGram’s Q4 2022 earnings at ($0.02) EPS, FY2022 earnings at ($0.09) EPS and FY2023 earnings at ($0.04) EPS.
OrganiGram (TSE:OGI – Get Rating) last released its earnings results on Tuesday, April 12th. The company reported C($0.03) earnings per share for the quarter, meeting the consensus estimate of C($0.03). The firm had revenue of C$31.84 million during the quarter, compared to the consensus estimate of C$30.58 million.
TSE:OGI opened at C$2.19 on Friday. OrganiGram has a 1-year low of C$1.65 and a 1-year high of C$4.26. The company has a current ratio of 8.40, a quick ratio of 6.60 and a debt-to-equity ratio of 1.67. The firm has a fifty day simple moving average of C$1.96 and a 200 day simple moving average of C$2.32. The stock has a market capitalization of C$686.98 million and a PE ratio of -6.29.
About OrganiGram (Get Rating)
Organigram Holdings Inc, through its subsidiaries, produces and sells cannabis and cannabis-derived products in Canada. It offers medical cannabis products, including cannabis flowers, cannabis oils, and vaporizers for civilian patients and veterans; adult use recreational cannabis under the Edison Cannabis Co, Trail Blazer, SHRED, SHRED'ems, Big Bag O' Buds, and Monjour brands; and cannabis edibles products and concentrates.
- Array Technologies Stock Giving Another Ground Floor Entry
- UiPath Stock is Nearing Rock Bottom Down Here
- 3 Undervalued S&P 500 Stocks to Buy Now
- 3 Undervalued Easter Eggs to Watch For This Earnings Season
- Lululemon Rises On Wave Of Price Target Increases
Receive News & Ratings for OrganiGram Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OrganiGram and related companies with MarketBeat.com's FREE daily email newsletter.